Abstract : Liver cancer is a major global health concern and most common histology is Hepatocellular Cell Carcinoma (HCC), accounting for 80% of cases. This tumor originates from hepatocytes and has increased due to risk factors like HBV, HCV and NASH. The prognosis of HCC is poor worldwide, influenced by the stage of diagnosis and the lack of curative therapies. This study was an analytic observational observational study conducted at Wahidin Sudirohusodo Hospital Makassar from December 2022 to August 2024. The population included patients with a diagnosis of HCC, complete medical record data and age over 18. Data extraction included etiology, cirrhosis, CTP, AFP, tumor size, thrombus, number of nodules, BCLC, therapy, gender, age, and life expectancy. Statistical test results were significant if the test p value <0.05. The study involved 95 patients with HCC, with an average age of 55.0±10.6 years. Hepatitis B was the most common cause 80 (84.2%). The study analyzed the association between characteristics hepatocellular carcinoma patients with 6-month survival. The AFP levels and Combination therapy were the most significant factors associated with 6-month survival. Patients with AFP levels <200 ng/mL at diagnosis had 1.9 times (OR=1.9; 95% CI= 1.01-3.60) and who received combination therapy had 6.3 times (OR= 6.3; 95% CI= 2.25-17.78) greater odds of 6-month survival. The study found that type of therapy and AFP value were the most significant factors, with AFP value <200 ng/mL and combination therapy being the most significant factor.